4th Quarter - Report

NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) for NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)

Firm
Client
Income
—
Expenses
$60,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Health issues impacting patients with rare diseases. Telehealth. Step Therapy. H.R.2279/S.2546: Safe Step Act. Notice of Benefit Payment Parameters. Surprise Medical Billing. Pre-Existing Conditions. User Fee Negotiations. Physician Fee Schedule. Value Based Purchasing. Integrated Review Panel. Regulation and Guidance Reform. Affordable Care Act. COVID-19 Related Issues.

LobbyistCovered position, as disclosed
CORINNE ALBERTS —
ROSE AVELLINO GALLAGHER —
HEIDI ROSS —
RICHARD WHITE New —

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE; Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES

Bills named: S. 2546 (116th), H.R. 2279 (116th)

Medicare/Medicaid MMM

Medicare issues impacting patients with rare diseases. Medicaid issues impacting patients with rare diseases. Medicare Part D Program. Section 1115 Medicaid Waivers. Medicaid Drug Rebates. Medicaid Expansion. Value-Based Payments. Prior Authorization.

LobbyistCovered position, as disclosed
CORINNE ALBERTS —
ROSE AVELLINO GALLAGHER —
HEIDI ROSS —

Contacted: SENATE; Food & Drug Administration (FDA); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Public Health Agency Appropriations.

LobbyistCovered position, as disclosed
HEIDI ROSS —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES

Pharmacy PHA

Pharmaceutical issues impacting patients with rare diseases. Prescription Drug Pricing. NBPP Proposed Rule. Biosimilar User Fee Act (BsUFA). Prescription Drug User Fee Act (PDUFA).

LobbyistCovered position, as disclosed
CORINNE ALBERTS —
HEIDI ROSS —
RICHARD WHITE New —

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.